Julie Le Naour Selected Research

Julie Le Naour Research Topics

Disease

13	Neoplasms (Cancer) 01/2023 - 01/2019
3	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2020
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2020
1	Colitis 01/2023
1	Carcinogenesis 01/2023
1	Breast Neoplasms (Breast Cancer) 01/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Ulcerative Colitis 01/2023
1	Fibrosarcoma 01/2023
1	Inflammation (Inflammations) 01/2023
1	Bites and Stings (Sting) 01/2020
1	Infections 01/2020
1	Condylomata Acuminata (Genital Wart) 01/2020
1	Actinic Keratosis 01/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2018

Drug/Important Bio-Agent (IBA)

3	Poly I-CIBA 01/2023 - 01/2020
3	LigandsIBA 01/2023 - 01/2020
3	Peptides (Polypeptides)IBA 01/2023 - 01/2020
3	Pattern Recognition ReceptorsIBA 01/2022 - 01/2020
3	VaccinesIBA 01/2021 - 01/2020
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2023 - 01/2020
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2019
2	AnthracyclinesIBA 01/2021 - 01/2021
2	CytokinesIBA 01/2021 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2020
2	InterferonsIBA 01/2020 - 01/2020
2	B7-H1 AntigenIBA 01/2020 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 01/2019
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2023
1	MutagensIBA 01/2023
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2023
1	Toll-Like Receptor AgonistsIBA 01/2023
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2023
1	cyclosporin HIBA 01/2023
1	AntibodiesIBA 01/2023
1	AzoxymethaneIBA 01/2023
1	Sulindac (Copal)FDA LinkGeneric 01/2023
1	Detergents (Detergent)IBA 01/2023
1	Dextrans (Dextran)FDA Link 01/2023
1	Phenobarbital (Luminal)FDA Link 01/2023
1	PlatinumIBA 01/2022
1	X-Box Binding Protein 1IBA 01/2022
1	Alanine (L-Alanine)FDA Link 01/2022
1	Anesthetics (Anesthetic Agents)IBA 01/2022
1	Local AnestheticsIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Threonine (L-Threonine)FDA Link 01/2022
1	Activating Transcription Factor 4IBA 01/2022
1	Activating Transcription Factor 6IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 10/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2021
1	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2021
1	Annexin A1IBA 01/2021
1	CarcinogensIBA 01/2021
1	VTX-2337IBA 01/2020
1	AntigensIBA 01/2020
1	Mucin-1 (CA 15-3 Antigen)IBA 01/2020
1	Poly A-UIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2020
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2020
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020
1	Imiquimod (Aldara)FDA LinkGeneric 01/2020
1	resiquimodIBA 01/2020
1	InterleukinsIBA 01/2020
1	Interferon Type IIBA 01/2020
1	hydroxycitric acidIBA 01/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	SpermidineIBA 01/2019
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2019
1	Immune Checkpoint ProteinsIBA 01/2019
1	DefensinsIBA 10/2018

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2023 - 01/2019
4	Therapeutics 01/2023 - 01/2020
2	Radiotherapy 01/2021 - 01/2020
2	Immunotherapy 01/2021 - 01/2021
1	Chemoradiotherapy 01/2023
1	Caloric Restriction 01/2019